Bildkälla: Stockfoto

Active Biotech Q4 2022: Laquinimod Ready for Phase II - Redeye

Redeye comments on Active Biotech's report for the fourth quarter and discusses events and the status of the clinical programs.

Redeye comments on Active Biotech's report for the fourth quarter and discusses events and the status of the clinical programs.
Börsvärldens nyhetsbrev
ANNONSER